KalVista Pharmaceuticals Stock (NASDAQ:KALV)
Previous Close
$9.05
52W Range
$7.39 - $16.88
50D Avg
$11.14
200D Avg
$12.24
Market Cap
$436.49M
Avg Vol (3M)
$391.10K
Beta
0.91
Div Yield
-
KALV Company Profile
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; KVD824, an oral product candidate for the treatment of HAE; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.
KALV Performance
Peer Comparison
Ticker | Company |
---|---|
DICE | DICE Therapeutics, Inc. |
GOSS | Gossamer Bio, Inc. |
CGEM | Cullinan Oncology, Inc. |
DYN | Dyne Therapeutics, Inc. |
VRDN | Viridian Therapeutics, Inc. |
LRMR | Larimar Therapeutics, Inc. |
EWTX | Edgewise Therapeutics, Inc. |
IMCR | Immunocore Holdings plc |
COGT | Cogent Biosciences, Inc. |
REPL | Replimune Group, Inc. |
SNDX | Syndax Pharmaceuticals, Inc. |
KRON | Kronos Bio, Inc. |
CRNX | Crinetics Pharmaceuticals, Inc. |
MRSN | Mersana Therapeutics, Inc. |
KURA | Kura Oncology, Inc. |
CYTK | Cytokinetics, Incorporated |
KRTX | Karuna Therapeutics, Inc. |
LYRA | Lyra Therapeutics, Inc. |
NVCT | Nuvectis Pharma, Inc. |
MIRM | Mirum Pharmaceuticals, Inc. |